New Developments in Incretins and SGLT Inhibitors episode artwork

EPISODE · Jun 19, 2009 · 14 MIN

New Developments in Incretins and SGLT Inhibitors

from Diabetes Discourse

Host: Steven Edelman, MD Guest: Robert Henry, MD The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastric emptying and appetite suppression. Join host Dr. Steven Edelman and his guest Dr. Robert Henry, professor of medicine at the University of California, San Diego, and chief of both the section of endocrinology, metabolism and diabetes and the Center for Metabolic Research at the VA Medical Center in San Diego.

Episode metadata supplied by the publisher feed · Published Jun 19, 2009

Embed this episode

NOW PLAYING

New Developments in Incretins and SGLT Inhibitors

0:00 14:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Diabetes Discourse?

This episode is 14 minutes long.

When was this Diabetes Discourse episode published?

This episode was published on June 19, 2009.

Can I download this Diabetes Discourse episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!